Trials / Completed
CompletedNCT00329264
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 876 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine fumarate |
Timeline
- Start date
- 2006-04-01
- Completion
- 2007-08-01
- First posted
- 2006-05-24
- Last updated
- 2009-03-25
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00329264. Inclusion in this directory is not an endorsement.